Tobrex®
Tobramycin 0.3% · ophthalmic solution
Antibiotic
Approved uses
Mild to moderate external infections of the eye and its adnexa caused by susceptible bacteria
1 or 2 drops into the affected eye(s) every 4 hours (mild to moderate disease)
About 90% clinical cure by day 7, and cure sustained to day 12 after a 7-day course.
Severe external ocular infection
2 drops into the affected eye(s) hourly until improvement, then reduce frequency before discontinuing
OFF-LABELNot in the FDA label for this product
Bacterial keratitis, as fortified tobramycin 1.3% with cefazolin 5%
Fortified tobramycin 1.3%: 1 to 2 drops every 30 minutes for 6 hours, then hourly for the rest of day 1, hourly on days 2 to 3, every 2 hours on days 4 to 5, every 4 hours on days 6 to 14, with cefazolin 5% instilled 5 to 15 minutes after each dose
RCT · n=324 · compounded
Randomized, double-masked, multicenter trial in 324 patients (176 culture-positive evaluable): fortified tobramycin plus cefazolin achieved 86.2% clinical success versus 91.5% for ciprofloxacin 0.3% monotherapy (P = 0.34, no significant difference), with significantly more discomfort on the fortified regimen (P = 0.01). The regimen studied was a compounded 1.3% concentration, not the commercial 0.3% solution.
Antibacterial cover after penetrating keratoplasty
1 drop QID until complete re-epithelialization (with topical dexamethasone)
RCT · n=46 · not prophylaxis
Prospective single-center randomized trial, 46 patients: mean time to complete re-epithelialization was 4.14 ± 1.17 days with Tobrex versus 4.13 ± 1.82 days with azithromycin (P = 0.89), and superficial punctate keratitis scores were similar (1.39 versus 1.34). No infection occurred in either arm, so the trial speaks to healing and tolerance, not to prophylactic efficacy.
Contraindications
Known hypersensitivity to tobramycin or any component of the formulation.
Ophthalmic solution, 2 mL, 5 mL dropper bottles, 0.3% (3 mg/mL)
Water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens. In vitro coverage includes staphylococci (penicillin-resistant strains included), some streptococci, Pseudomonas aeruginosa and other gram-negatives; in some cases microorganisms resistant to gentamicin retain susceptibility to tobramycin. Aminoglycosides inhibit bacterial protein synthesis by binding to the 30S subunit, which blocks the initiation complex.
Warnings & Precautions
- Not for injection into the eye: For topical ophthalmic use.
- Aminoglycoside hypersensitivity: Sensitivity to topically applied aminoglycosides may occur in some patients, and severity may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions; discontinue use if a sensitivity reaction occurs.
- Aminoglycoside cross-sensitivity: Cross-sensitivity to other aminoglycoside antibiotics may occur; if hypersensitivity develops, discontinue use and institute appropriate therapy.
- Superinfection: Prolonged use may result in overgrowth of nonsusceptible organisms, including fungi; if superinfection occurs, appropriate therapy should be initiated.
- Neurotoxicity, ototoxicity and nephrotoxicity: These have occurred in patients receiving systemic aminoglycoside therapy, and aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson's disease.
- Contact lens wear: Not advised while signs and symptoms of bacterial ocular infection are present.
- Dropper tip contamination: Do not touch the dropper tip to any surface, as this may contaminate the solution.
- Corneal epithelial toxicity: In a rabbit wound-healing model of eight topical antibiotic solutions, gentamicin sulfate, tobramycin, and chloramphenicol were the most toxic, and fortified preparations of gentamicin and tobramycin did not seem more toxic than the 0.3% solutions; the authors concluded that not all antibiotics should be considered innocuous when used in the treatment of epithelial defects.
Common Side Effects
The most frequent adverse reactions are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema, and these reactions occur in less than three of 100 patients treated. Additional adverse reactions identified from postmarketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme.
Pregnancy: Reproduction studies in 3 types of animals at doses up to 33 times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus; there are no adequate and well controlled studies in pregnant women, and because animal studies are not always predictive of human response, use during pregnancy only if clearly needed.
Lactation: Because of the potential for adverse reactions in nursing infants, decide whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Not established below age 2 months.